<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234556</url>
  </required_header>
  <id_info>
    <org_study_id>4P-16-7</org_study_id>
    <secondary_id>NCI-2017-00890</secondary_id>
    <secondary_id>4P-16-7</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <secondary_id>R01CA205058</secondary_id>
    <nct_id>NCT03234556</nct_id>
  </id_info>
  <brief_title>Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA</brief_title>
  <official_title>Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well systematic random biopsy or magnetic&#xD;
      resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate&#xD;
      cancer in patients with elevated prostate specific antigen. Systematic random biopsy and&#xD;
      MRI-US fusion biopsy may work better in improving the accuracy of prostate cancer detection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the detection of clinically significant prostate cancer (CSPCa) in Arm 1 versus&#xD;
      Arm 2.&#xD;
&#xD;
      II. To compare between African American (AA) and white men the probability of developing&#xD;
      CSPCa within three years of initial biopsy at the start of the study.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine complications and patient morbidity associated with either systematic random&#xD;
      prostate biopsy (SR-Bx) versus (vs) magnetic resonance imaging-ultrasound image fusion biopsy&#xD;
      (MRUS-Bx) + SR-Bx.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To compare Gleason score between MRUS-Bx and radical prostatectomy (RP) specimen among men&#xD;
      who elect RP (~110 in the randomized controlled trial [RCT]).&#xD;
&#xD;
      II. To assess within Arm 1 the detection of CSPCa three months after SR-Bx among men&#xD;
      initially diagnosed with clinically insignificant prostate cancer (CinsPCa) or no cancer.&#xD;
&#xD;
      III. To identify among men invited to participate and those actually enrolled in the RCT:&#xD;
      determinants of study participation.&#xD;
&#xD;
      IV. To identify among men invited to participate and those actually enrolled in the RCT:&#xD;
      determinants of treatment decision (active surveillance [AS] vs radiation vs RP) including&#xD;
      the diagnostic method.&#xD;
&#xD;
      OUTLINE: Patients are randomized into 1 of 2 arms.&#xD;
&#xD;
      ARM I: SR-Bx group&#xD;
&#xD;
        -  Patients undergo SR-Bx&#xD;
&#xD;
             -  If SR-Bx doesn't reveal clinically significant cancer, then MRI in 3 months, and if&#xD;
                lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx.&#xD;
&#xD;
             -  If there is no lesion, then no biopsy - schedule MRI in 12 months after the initial&#xD;
                MRI.&#xD;
&#xD;
      ARM II: MRUS-Bx group&#xD;
&#xD;
        -  Patients undergo MRI. Must be scheduled at least 1 day before MRUS Biopsy.&#xD;
&#xD;
             -  MRI shows no lesion present (PIRADS 1-2): no MRUS-Bx, schedule for SR-Bx only.&#xD;
&#xD;
             -  MRI lesion present (PIRADS ≥ 3): schedule for MRUS-Bx, which will be done first and&#xD;
                followed immediately after by SR-Bx.&#xD;
&#xD;
      FOLLOW UP:&#xD;
&#xD;
      After completion of procedure, patients are followed up at 2-4 weeks, 3, 6, 9, and 12 months,&#xD;
      and then periodically for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Anticipated">September 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy detection rate of clinically significant prostate cancer</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will code patients as having clinically significant prostate cancer if they are diagnosed with Gleason score &gt;= 7 or any Gleason score with core length &gt;= 5 mm or any Gleason score that includes Gleason pattern &gt;= 4 at initial systematic random biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of any of the complications</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be summarized in the complications checklist. Will determine any striking co-morbidities that are present post-biopsy and were absent pre-biopsy within each arm, and next determine if the prevalence of any of these identified post-biopsy morbidities differs between the two arms. For these analyses, regression methods (linear, logistic, multinomial logistic as appropriate for the &quot;dependent&quot; variable being analyzed) will be used. Standard descriptive methods will be used to summarize and display the results.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Highest Gleason score</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will assess the highest Gleason score in magnetic resonance imaging-ultrasound image fusion biopsy and systematic random biopsy. Will evaluated using agreement metrics such as percent agreement, Cohen's kappa (k) statistic and Krippendorff's alpha statistic. Significance will be considered if p &lt; 0.05.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Health Status Unknown</condition>
  <condition>Elevated PSA</condition>
  <arm_group>
    <arm_group_label>Arm I (SR-Bx)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (MRI, MRUS-Bx, SR-Bx)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.&#xD;
If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.&#xD;
If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy of Prostate</intervention_name>
    <description>Undergo SR-Bx</description>
    <arm_group_label>Arm I (SR-Bx)</arm_group_label>
    <arm_group_label>Arm II (MRI, MRUS-Bx, SR-Bx)</arm_group_label>
    <other_name>Prostate Biopsy</other_name>
    <other_name>Prostatic Biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (SR-Bx)</arm_group_label>
    <arm_group_label>Arm II (MRI, MRUS-Bx, SR-Bx)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI</description>
    <arm_group_label>Arm I (SR-Bx)</arm_group_label>
    <arm_group_label>Arm II (MRI, MRUS-Bx, SR-Bx)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI Ultrasound Fusion Guided Biopsy</intervention_name>
    <description>Undergo MRUS-Bx</description>
    <arm_group_label>Arm I (SR-Bx)</arm_group_label>
    <arm_group_label>Arm II (MRI, MRUS-Bx, SR-Bx)</arm_group_label>
    <other_name>Fusion Biopsy</other_name>
    <other_name>Fusion-Guided Biopsy</other_name>
    <other_name>MR Fusion Biopsy</other_name>
    <other_name>MRI-Ultrasound Fusion Biopsy</other_name>
    <other_name>MRI/Ultrasound Fusion Biopsy</other_name>
    <other_name>MRI/US Biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent and Health Insurance Portability and Accountability Act&#xD;
             (HIPAA) authorization for release of personal health information&#xD;
&#xD;
               -  Note: HIPAA authorization may be included in the informed consent or obtained&#xD;
                  separately&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 1 within 3 months&#xD;
             (93 days) prior to being registered for protocol&#xD;
&#xD;
          -  African-American or white men (Hispanic or non-Hispanic)&#xD;
&#xD;
          -  Prostate biopsy-naive or a single negative biopsy&#xD;
&#xD;
          -  Having elevated prostate specific antigen (PSA) (&gt; 2.5 ng/ml) and no palpable nodule&#xD;
             on digital rectal exam (DRE)&#xD;
&#xD;
          -  Ability to understand the willingness to sign a written informed consent&#xD;
&#xD;
          -  Patients must be willing to undergo a radiologic imaging before and after biopsy of&#xD;
             the prostate&#xD;
&#xD;
          -  Patients must be willing to undergo a biopsy of the prostate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 12 months of the study for&#xD;
             other diagnoses not related to prostate cancer&#xD;
&#xD;
          -  Patients receiving any other investigational agents&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Patients with active inflammatory bowel disease&#xD;
&#xD;
          -  Patients who are unable to undergo MRI&#xD;
&#xD;
          -  Patients who had any surgery of the prostate including TURP (transurethral resection&#xD;
             of the prostate)&#xD;
&#xD;
          -  Patients who had &gt; 1 prior prostate biopsy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inderbir Gill</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ileana Aldana</last_name>
    <phone>323-865-0702</phone>
    <email>Ileana.aldana@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ileana Aldana</last_name>
      <phone>323-865-0702</phone>
      <email>Ileana.aldana@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Inderbir Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganine Markowitz-Chrystal</last_name>
      <phone>410-328-0800</phone>
      <email>gmarkowitz@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Minhaj Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inderbir Gill</last_name>
      <phone>323-865-3000</phone>
    </contact>
    <investigator>
      <last_name>Inderbir Gill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inderbir Gill</last_name>
      <phone>323-865-3000</phone>
    </contact>
    <investigator>
      <last_name>Inderbir Gill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital Vattikuti Urology Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali A. Dabaja, MD</last_name>
      <phone>313-717-8680</phone>
      <email>adabaja2@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Mustafa Deebajah</last_name>
      <phone>313-717-8680</phone>
      <email>Mdeebaj1@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>James Peabody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Coleman, MD</last_name>
      <phone>646-422-4432</phone>
      <email>colemanj@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inderbir Gill</last_name>
      <phone>323-865-3000</phone>
    </contact>
    <investigator>
      <last_name>Inderbir Gill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

